在日常临床实践中，那他珠单抗作为多发性硬化症的二线治疗药物效果如何？ - Suppr

Suppr

超能文献

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

作者信息

Sorensen P S

出版信息

Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x.

DOI:10.1111/j.1468-1331.2008.02518.x

PMID:19364360

Abstract

摘要

相似文献

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

Eur J Neurol. 2009 Mar;16(3):420-3. doi: 10.1111/j.1468-1331.2008.02517.x.

[Choice of early and escalation treatment options for multiple sclerosis].

Nervenarzt. 2008 Oct;79(10):1123-4,1126-8,1130-2 passim. doi: 10.1007/s00115-008-2521-3.

[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Nervenarzt. 2006 Dec;77(12):1506-18. doi: 10.1007/s00115-006-2220-x.

[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].

Nervenarzt. 2007 Sep;78 Suppl 1:15-24; quiz 25. doi: 10.1007/s00115-007-2327-8.

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9.

Natalizumab for relapsing multiple sclerosis.

N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. doi: 10.1056/NEJMc060894.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15.

Natalizumab (Tysabri) returns.

Med Lett Drugs Ther. 2006 Sep 11;48(1243):76.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

作者信息

Sorensen P S

出版信息

Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x.

DOI:10.1111/j.1468-1331.2008.02518.x

PMID:19364360

Abstract

摘要

相似文献

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

Eur J Neurol. 2009 Mar;16(3):420-3. doi: 10.1111/j.1468-1331.2008.02517.x.

[Choice of early and escalation treatment options for multiple sclerosis].

Nervenarzt. 2008 Oct;79(10):1123-4,1126-8,1130-2 passim. doi: 10.1007/s00115-008-2521-3.

[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Nervenarzt. 2006 Dec;77(12):1506-18. doi: 10.1007/s00115-006-2220-x.

[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].

Nervenarzt. 2007 Sep;78 Suppl 1:15-24; quiz 25. doi: 10.1007/s00115-007-2327-8.

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9.

Natalizumab for relapsing multiple sclerosis.

N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. doi: 10.1056/NEJMc060894.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15.

Natalizumab (Tysabri) returns.

Med Lett Drugs Ther. 2006 Sep 11;48(1243):76.